TLR7 and neoplasm: Studies have shown that mannosylated nanoparticles delivering the TLR7/8 agonist R848 (Man-pD-PLGA-NP@R848) target tumor-associated macrophages (TAMs) through mannose receptor-mediated endocytosis, inducing their transition from the M2 (pro-tumor) to the M1 (anti-tumor) phenotype.